This page has only limited features, please log in for full access.
: The most common cause of mortality among people with type 1 diabetes is cardiovascular diseases. Arterial stiffness allows predicting cardiovascular complications, cardiovascular mortality, and all-cause mortality. There are different ways to measure arterial stiffness; the gold standard is pulse wave velocity. Arterial stiffness is increased in people with type 1 diabetes compared to healthy controls. It increases with age and duration of type 1 diabetes. Arterial stiffness among people with type 1 diabetes has a positive association with systolic blood pressure, obesity, glycated hemoglobin, waist circumference, and waist to hip ratio. It has a negative correlation with estimated glomerular filtration rate, high-density lipoprotein, and the absence of carotid plaques. The increased arterial stiffness could be the result of insulin resistance, collagen increase due to inadequate enzymatic glycation, endothelial and autonomic dysfunction. The insulin-induced decrease in arterial stiffness is impaired in type 1 diabetes. There are not enough proofs to use pharmacotherapy in the prevention of arterial stiffness, but some of the medicaments have obtained promising results in single studies, for example, renin-angiotensin-aldosterone system inhibitors, statins, and SGLT2 inhibitors. The main form of prevention of arterial stiffness progression remains glycemic control and a healthy lifestyle.
Michal Kulecki; Aleksandra Uruska; Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz. Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge. Current Diabetes Reviews 2021, 17, 1 -1.
AMA StyleMichal Kulecki, Aleksandra Uruska, Dariusz Naskret, Dorota Zozulinska-Ziolkiewicz. Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge. Current Diabetes Reviews. 2021; 17 ():1-1.
Chicago/Turabian StyleMichal Kulecki; Aleksandra Uruska; Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz. 2021. "Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge." Current Diabetes Reviews 17, no. : 1-1.
Atherosclerosis—considered the major cause of cardiovascular diseases (CVDs)—is strongly associated with obesity, to which it strongly contributes. Moreover, atherosclerosis is characterised by a long asymptomatic phase, and its progression can lead to serious cardiovascular (CV) events. The carotid intima-media thickness (cIMT) has been determined as a predictor of CV events, as well as a marker of subclinical atherosclerosis, and has been used in clinical trials as an alternative assessment method or a surrogate endpoint. It should be noted that several behavioural approaches can directly influence the cIMT values, and decrease or increase the CV risk. In our paper, we aimed to summarize the current knowledge regarding IMT measurement among patients with obesity as a risk group—also in terms of the obesity paradox where the diagnosis of subclinical atherosclerosis is especially essential and implements the early therapeutic approach. We also summarized behavioural, modifiable factors, such as the Mediterranean diet, the Dietary Approach to Stop Hypertension Diets, body weight reduction or the intake of micro- and macronutrients, with a particular focus on the studies where the cIMT values were one of the outcomes. In order to collect the literature data related to the presented topic, the PubMed database was explored.
Anna Rychter; Dariusz Naskręt; Agnieszka Zawada; Alicja Ratajczak; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak. What Can We Change in Diet and Behaviour in Order to Decrease Carotid Intima-Media Thickness in Patients with Obesity? Journal of Personalized Medicine 2021, 11, 505 .
AMA StyleAnna Rychter, Dariusz Naskręt, Agnieszka Zawada, Alicja Ratajczak, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak. What Can We Change in Diet and Behaviour in Order to Decrease Carotid Intima-Media Thickness in Patients with Obesity? Journal of Personalized Medicine. 2021; 11 (6):505.
Chicago/Turabian StyleAnna Rychter; Dariusz Naskręt; Agnieszka Zawada; Alicja Ratajczak; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak. 2021. "What Can We Change in Diet and Behaviour in Order to Decrease Carotid Intima-Media Thickness in Patients with Obesity?" Journal of Personalized Medicine 11, no. 6: 505.
Introduction: Protein profiling allows the determination of the presence of proteins marking various stages of the disease, and differentiates between people at risk of various diseases. In type 1 diabetes, protein profiling had been previously used to find blood markers other than islet autoantibodies to indicate the pancreatic beta cell destruction process and to reflect the progression of type 1 diabetes mellitus (T1DM). However, T1DM is an auto-immune disease and its clinical presentation changes in time of its duration. The aim of the study: To find differences in protein profiles in patients with type 1 diabetes according to diabetes control (HbA1c > 7%) and with presence of diabetic complications or obesity. It may help to identify subgroups of patients who may need a better clinical supervision and individualized treatment. Material and methods: A group of 103 patients with auto-immunologically confirmed T1DM, and meeting the following inclusion criteria: Caucasian race, duration of diabetes >5 years, were used in the study. Criteria of exclusion: past or present cancer (treated with chemo-/radiotherapy), diseases of the liver (ALT > 3 × ULN) except for people with simple hepatic steatosis, chronic renal disease (eGFR < 30 mL/1.73 m2/min), and acute inflammation (CRP > 5 mg/dL). The study group was divided in terms of the presence of chronic complications, obesity, or poor metabolic control (HbA1c > 7%). Protein profiling was completed by using the MALDI-TOF MS (matrix-assisted laser desorption/ionization-time of flight mass spectrometry) analyzer. Results: Differentiating proteins were identified in all of the groups. The groups burdened with complications, obesity, and poor metabolic control were characterized by increased levels of fibrinogen, complement C4 and C3. Conclusion: The groups of type 1 diabetes patients burdened with complications, obesity, and poor metabolic control were characterized by increased levels of fibrinogen, complement C4 and C3. Further detailed studies are necessary to determine more subtle changes in the proteomic profile of patients with type 1 diabetes.
Agnieszka Zawada; Dariusz Naskręt; Eliza Matuszewska; Zenon Kokot; Marian Grzymisławski; Dorota Zozulińska-Ziółkiewicz; Agnieszka Dobrowolska; Jan Matysiak. MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications. International Journal of Environmental Research and Public Health 2021, 18, 2263 .
AMA StyleAgnieszka Zawada, Dariusz Naskręt, Eliza Matuszewska, Zenon Kokot, Marian Grzymisławski, Dorota Zozulińska-Ziółkiewicz, Agnieszka Dobrowolska, Jan Matysiak. MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications. International Journal of Environmental Research and Public Health. 2021; 18 (5):2263.
Chicago/Turabian StyleAgnieszka Zawada; Dariusz Naskręt; Eliza Matuszewska; Zenon Kokot; Marian Grzymisławski; Dorota Zozulińska-Ziółkiewicz; Agnieszka Dobrowolska; Jan Matysiak. 2021. "MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications." International Journal of Environmental Research and Public Health 18, no. 5: 2263.
The process of protein glycation described by Brownlee et al. is a crucial pathogenic mechanism in the development of chronic complications of diabetes. To assess advanced glycation end products (AGEs) in the skin of patients with type 1 diabetes (DM1) and excess body fat (EBF) accumulation. The study group consisted of 227 DM1 patients (121 women and 106 men) whose mean age was 31 ±9.2 years; the mean duration of diabetes was 12 ±7.7 years; and the mean HbA1c was 8.9 ±1.8%. The inclusion criteria were as follows: age 18-65 years, DM1, and lack of acute inflammations and uncontrolled chronic diseases. The exclusion criteria were: anemia (hemoglobin (Hb) <11 g/dL), chronic kidney disease (CKD) (glomerular filtration rate (eGFR) <30 mL/min/1.73 m2) and elevated aminotransferase levels (more than twice the upper normal limits). Total adipose tissue content was assessed using the electrical bioimpedance method, with the Tanita BC-418 MA analyzer (Tanita Corp., Tokyo, Japan). The Tanita ViScan AB 140 (Tanita Corp.) was used to evaluate visceral fat tissue (VTF). The content of glycation end products in the skin was assessed using a DiagnOptics AGE Reader device (type 214D00102; DiagnOptics, Groningen, the Netherlands). The group with normal body fat (NBF) consisted of 123 subjects, whereas 104 subjects had EBF. No significant statistical differences were found between the NBF and EBF groups with regard to age, duration of diabetes, current HbA1C value, and tobacco use. A significantly higher AGE score was observed in the EBF group. Increased body fat affects the amount of AGE in the skin, which correlates with a higher risk of developing chronic diabetes complications.
Agnieszka Ewa Zawada; Dariusz Naskret; Paweł Niedźwiecki; Marian Grzymisławski; Dorota Anna Zozulińska-Ziółkiewicz; Agnieszka Dobrowolska. Excess body fat increases the accumulation of advanced glycation end products in the skin of patients with type 1 diabetes. Advances in Clinical and Experimental Medicine 2020, 29, 1193 -1199.
AMA StyleAgnieszka Ewa Zawada, Dariusz Naskret, Paweł Niedźwiecki, Marian Grzymisławski, Dorota Anna Zozulińska-Ziółkiewicz, Agnieszka Dobrowolska. Excess body fat increases the accumulation of advanced glycation end products in the skin of patients with type 1 diabetes. Advances in Clinical and Experimental Medicine. 2020; 29 (10):1193-1199.
Chicago/Turabian StyleAgnieszka Ewa Zawada; Dariusz Naskret; Paweł Niedźwiecki; Marian Grzymisławski; Dorota Anna Zozulińska-Ziółkiewicz; Agnieszka Dobrowolska. 2020. "Excess body fat increases the accumulation of advanced glycation end products in the skin of patients with type 1 diabetes." Advances in Clinical and Experimental Medicine 29, no. 10: 1193-1199.
Agata Grzelka; Dariusz Naskręt; Aleksandra Araszkiewicz; Aleksandra Uruska; Małgorzata Wegner; Dorota Zozulinska-Ziolkiewicz. Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study. Advances in Clinical and Experimental Medicine 2017, 26, 1343 -1349.
AMA StyleAgata Grzelka, Dariusz Naskręt, Aleksandra Araszkiewicz, Aleksandra Uruska, Małgorzata Wegner, Dorota Zozulinska-Ziolkiewicz. Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study. Advances in Clinical and Experimental Medicine. 2017; 26 (9):1343-1349.
Chicago/Turabian StyleAgata Grzelka; Dariusz Naskręt; Aleksandra Araszkiewicz; Aleksandra Uruska; Małgorzata Wegner; Dorota Zozulinska-Ziolkiewicz. 2017. "Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study." Advances in Clinical and Experimental Medicine 26, no. 9: 1343-1349.
Background: The aim of this study was to assess the hemodynamic parameters analyzed in bioimpedance cardiography during maximal exercise in patients with type 1 diabetes differing in insulin resistance. Methods: The study group consisted of 40 men with type 1 diabetes. Tissue sensitivity to insulin was assessed on the basis of the glucose disposal rate (GDR) analyzed during hyperinsulinemic–euglycemic clamp. Patients were divided into groups with GDR <4.5 mg/kg/min (G1 group—lower insulin sensitivity) and GDR ≥4.5 mg/kg/min (G2 group—higher insulin sensitivity). During the exercise test, the heart rate, systolic volume, cardiac output, cardiac index were measured by the impedance meter (PhysioFlow). Results: Compared with the G2 group, the G1 group had a lower cardiac output (CO): during exercise 8.6 (IQR 7.7–10.0) versus 12.8 (IQR 10.8–13.7) L/min; P < 0.0001, at the maximal effort 13.1 (IQR 12.2–16.7) versus 18.6 (IQR 16.9–20.2) L/min; P = 0.001, and during observation after exercise 8.4 (IQR 6.3–9.6) versus 11.9 (IQR 10.1–13.1) L/min; P < 0.0001. We noticed a positive correlation of GDR and cardiac output: during the exercise test (r = 0.63, P = 0.0002), at the maximal effort (Rs 0.56, P = 0.001), and during observation after the exercise test (r = 0.72, P < 0.0001). In multivariate logistic regression, cardiac output during exercise and during observation was associated with high GDR, regardless of the age and duration of diabetes [OR: 1.98 (95% CI 1.10–3.56), P = 0.02 and OR: 1.91 (95% CI 1.05–3.48), P = 0.03; respectively]. Conclusion: In nonobese subjects with type 1 diabetes, with good metabolic control, insulin resistance is associated with cardiac hemodynamic parameters assessed during and after exercise. The higher the insulin resistance the lower the cardiac output during maximal exercise in men with type 1 diabetes.
Pawel Niedzwiecki; Dariusz Naskret; Stanislaw Pilacinski; Maciej Pempera; Aleksandra Uruska; Anna Adamska; Dorota Zozulinska-Ziolkiewicz. The Higher the Insulin Resistance the Lower the Cardiac Output in Men with Type 1 Diabetes During the Maximal Exercise Test. Metabolic Syndrome and Related Disorders 2017, 15, 252 -257.
AMA StylePawel Niedzwiecki, Dariusz Naskret, Stanislaw Pilacinski, Maciej Pempera, Aleksandra Uruska, Anna Adamska, Dorota Zozulinska-Ziolkiewicz. The Higher the Insulin Resistance the Lower the Cardiac Output in Men with Type 1 Diabetes During the Maximal Exercise Test. Metabolic Syndrome and Related Disorders. 2017; 15 (5):252-257.
Chicago/Turabian StylePawel Niedzwiecki; Dariusz Naskret; Stanislaw Pilacinski; Maciej Pempera; Aleksandra Uruska; Anna Adamska; Dorota Zozulinska-Ziolkiewicz. 2017. "The Higher the Insulin Resistance the Lower the Cardiac Output in Men with Type 1 Diabetes During the Maximal Exercise Test." Metabolic Syndrome and Related Disorders 15, no. 5: 252-257.
The purpose of this study was to evaluate the impact of high intensity exercise on glucose levels and risk of metabolic decompensation in males with type 1 diabetes (T1D), depending on the method of insulin administration. The study comprised 29 males (aged 25.3±5.1 years; duration of diabetes 10.3±3.2 years) treated with continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injections (MDI). Treadmill exercise test was performed twice in each patient until subjective exhaustion as maximum according to the Borg scale. All the patients achieved ≥85% of the maximal heart rate. Distance during the test was 4 500±1 400 m and 4 473±1 559 m in the MDI and CSII groups, respectively, which was achieved in 31±8 min. During the test and in the 6 h after, no clinically significant episodes of hypoglycemia occurred. Mean glucose levels did not exceed 10 mmol/L in most patients. The risk of the composite endpoint (hypoglycemia2.2 mmol/L) was higher in patients treated with MDI than CSII (OR3.75, 95%CI:1.22–11.52, p=0.02). In conclusion, planned high intensity physical effort in men with well-controlled T1D is metabolically safe. CSII shows greater metabolic advantage over MDI during and after high intensity exercise in men with T1D.
Andrzej Gawrecki; Dariusz Naskret; Pawel Niedzwiecki; Anna Duda-Sobczak; Aleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz. High-intensity Exercise in Men with Type 1 Diabetes and Mode of Insulin Therapy. International Journal of Sports Medicine 2017, 38, 329 -335.
AMA StyleAndrzej Gawrecki, Dariusz Naskret, Pawel Niedzwiecki, Anna Duda-Sobczak, Aleksandra Araszkiewicz, Dorota Zozulinska-Ziolkiewicz. High-intensity Exercise in Men with Type 1 Diabetes and Mode of Insulin Therapy. International Journal of Sports Medicine. 2017; 38 (4):329-335.
Chicago/Turabian StyleAndrzej Gawrecki; Dariusz Naskret; Pawel Niedzwiecki; Anna Duda-Sobczak; Aleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz. 2017. "High-intensity Exercise in Men with Type 1 Diabetes and Mode of Insulin Therapy." International Journal of Sports Medicine 38, no. 4: 329-335.
INTRODUCTION Lipoprotein-associated phospholipase A2 (Lp-PLA2) and cholesteryl ester lipase (CEL) may oxidize low-density lipoproteins (oxLDL). OBJECTIVES The aim of the study was to determine the influence of metformin on the metabolism of atherogenic lipid fractions in relation to Lp-PLA2 and CEL levels, as well as assess consequent improvement in the intima-media thickness (IMT) of the common carotid artery in young type 1 diabetes patients with excess body fat. PATIENTS AND METHODS It was an open-label randomized clinical trial that lasted 6 months. It included a total of 84 people with metabolic decompensation (glycated hemoglobin >7.5%, >58.5 mmol/mol) of diabetes. Adjunctive metformin therapy (in addition to insulin) was administered in 42 patients, and the remaining 42 patients received insulin alone. Glycated low-density lipoproteins (LDLs), oxLDL, Lp-PLA2, and CEL were assessed by commercially available enzyme-linked immunosorbent assay kits. Cartoid IMT was measured using the Carotid Analyser for Research tool. Biochemical analyses were performed using routine laboratory techniques. RESULTS The reduction of mean carotid IMT was observed in young type 1 diabetic adults treated additionally with metformin (0.6 ±0.1 cm vs 0.53 ±0.1 cm; P = 0.002). This effect was probably due to weight reduction (90 ±16 kg vs 87 ±15 kg, P = 0.054) and the decrease in atherogenic glycated LDL levels (1.5 ±0.5 mg/dl vs 1.6 ±1.046 mg/dl, P = 0.006). No such correlations were observed in patients treated with insulin alone. Additionally, in patients receiving metformin, glycated LDL levels were inversely correlated with Lp-PLA2 levels (r = -0.31, P <0.05). CONCLUSIONS Additional use of metformin in young type 1 diabetic patients with excess body fat leads to a significant reduction of mean IMT in the common carotid artery. Concentrations of CEL and Lp-PLA2 were significantly increased in both study arms despite improved glucose metabolism.
Paweł Burchardt; Agnieszka Zawada; Jolanta Kaczmarek; Justyna Marcinkaniec; Henryk Wysocki; Bogna Wierusz-Wysocka; Marian Grzymisławski; Dorota Zozulinska-Ziolkiewicz; Janusz Rzeźniczak; Dariusz Naskręt. Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness. Polish Archives of Internal Medicine 2016, 126, 514 -20.
AMA StylePaweł Burchardt, Agnieszka Zawada, Jolanta Kaczmarek, Justyna Marcinkaniec, Henryk Wysocki, Bogna Wierusz-Wysocka, Marian Grzymisławski, Dorota Zozulinska-Ziolkiewicz, Janusz Rzeźniczak, Dariusz Naskręt. Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness. Polish Archives of Internal Medicine. 2016; 126 (7):514-20.
Chicago/Turabian StylePaweł Burchardt; Agnieszka Zawada; Jolanta Kaczmarek; Justyna Marcinkaniec; Henryk Wysocki; Bogna Wierusz-Wysocka; Marian Grzymisławski; Dorota Zozulinska-Ziolkiewicz; Janusz Rzeźniczak; Dariusz Naskręt. 2016. "Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness." Polish Archives of Internal Medicine 126, no. 7: 514-20.
Prevalence of partial remission ranges between 20% and 80% in the initial course of type 1 diabetes. In this phase of the disease, a substantial insulin secretion contributes to good metabolic control. The aim of the study was to determine the association between presence of partial remission and occurrence of microangiopathy complications in type 1 diabetes. Ninety-eight consecutive patients with newly diagnosed type 1 diabetes were asked to participate in a cohort study. Partial remission was defined as the time in which all of the following criteria were met: HbA1c below 6.5% (48mmol/mol), daily insulin requirement below 0.3 U/kg body weight and serum Cpeptide concentration above 0.5ng/ml. Patients were divided into those who were in remission at any time during follow-up (remitters) and non-remitters. After 7years of follow-up, the occurrence of microangiopathy complications was analyzed. In statistical analysis, Mann-Whitney test, chi(2) test and Fisher test were used for analysis between groups. We applied a Cox's multivariate regression model and univariate regression method. P<0.05 was considered statistically significant. In univariate logistic regression, a significant association was found between absence of remission and occurrence of at least one microvascular complication. In the Cox proportional hazards regression model that included clinically significant parameters at diagnosis (presence of ketoacidosis, cigarette smoking and HbA1c value) as covariates, absence of remission was associated with occurrence of chronic complications of diabetes at 7years [HR: 3.65 (95% CI 1.23-4.56), p=0.04]. In non-remitters, higher incidence of at least one microvascular complication (46.4% vs. 7.6%), higher incidence of retinopathy (42.8% vs. 5.7%), and neuropathy (21.4% vs. 1.9%) was found. Occurrence of partial remission of diabetes is associated with a reduced risk of chronic microvascular complications at 7-year follow-up.
Pawel Niedzwiecki; Stanislaw Pilacinski; Aleksandra Uruska; Anna Adamska; Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz. Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes. Journal of Diabetes and its Complications 2015, 29, 1105 -1111.
AMA StylePawel Niedzwiecki, Stanislaw Pilacinski, Aleksandra Uruska, Anna Adamska, Dariusz Naskret, Dorota Zozulinska-Ziolkiewicz. Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes. Journal of Diabetes and its Complications. 2015; 29 (8):1105-1111.
Chicago/Turabian StylePawel Niedzwiecki; Stanislaw Pilacinski; Aleksandra Uruska; Anna Adamska; Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz. 2015. "Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes." Journal of Diabetes and its Complications 29, no. 8: 1105-1111.
Our aim was to assess the association between skin autofluorescence (AF) related to advanced glycation end products (AGEs) accumulation and long-term metabolic control, microvascular complications and carotid intima-media thickness (IMT) in an observational cohort of type 1 diabetes (DM1).The analysis included 77 patients with DM1 (28 women and 49 men) aged 38 (IQR: 34-41), diabetes duration 15 (14-17), participating in Poznan Prospective Study (PoProStu). Skin AF was measured with AGE Reader (DiagnOptics).We found 50% of any microvascular complication; 37% of retinopathy, 37% of diabetic kidney disease and 22% of distal symmetrical neuropathy. Median carotid IMT was 0.57 (0.52-0.67) mm and skin AF 2.2 (IQR: 1.9-2.6). We found positive correlation between skin AF and patients' age (r=0.31, p=0.006), mean HbA1c from the observation time (r=0.35, p=0.001) and IMT (r=0.39, p<0.001). In multivariate logistic regression presence of microvascular complications was independently associated with skin AF: for retinopathy (OR 3.49; 95% CI: 1.08-11.28, p=0.03), for diabetic kidney disease (OR 3.62; 95% CI: 1.16-11.28, p=0.02), for neuropathy (OR 5.01; 95% CI: 1.21-20.77, p=0.02) and for any microangiopathy (OR 3.13; 95% CI: 1.06-9.18, p=0.03).Skin AF is a reliable marker of past glycemic control of diabetes. Increased accumulation of AGEs is related to the presence of diabetic microangiopathy as well as subclinical macroangiopathy in patients with type 1.
Aleksandra Araszkiewicz; Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz; Stanislaw Pilacinski; Aleksandra Uruska; Agata Grzelka; Malgorzata Wegner; Bogna Wierusz-Wysocka. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study. Microvascular Research 2015, 98, 62 -67.
AMA StyleAleksandra Araszkiewicz, Dariusz Naskret, Dorota Zozulinska-Ziolkiewicz, Stanislaw Pilacinski, Aleksandra Uruska, Agata Grzelka, Malgorzata Wegner, Bogna Wierusz-Wysocka. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study. Microvascular Research. 2015; 98 ():62-67.
Chicago/Turabian StyleAleksandra Araszkiewicz; Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz; Stanislaw Pilacinski; Aleksandra Uruska; Agata Grzelka; Malgorzata Wegner; Bogna Wierusz-Wysocka. 2015. "Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study." Microvascular Research 98, no. : 62-67.
The use of exogenous insulin and incorrect nutritional habits are conducive to obesity and excess weight. This leads to the development of insulin resistance, even in patients with type 1 diabetes mellitus. The aim of this study was to assess the effects of metformin as adjunctive therapy on anthropometric parameters and metabolic control in patients with type 1 diabetes mellitus. The study included a group 45 patients with elevated adipose tissue content as measured by electrical bioimpedance. Thirty-nine patients (11 males and 28 females) of the group fulfill the study protocol. The mean age was 33.5 ± 11.9 years and duration of diabetes 12.6 ± 7.4 years. Metformin was administered for at least 6 months at a mean dose of 1032 ± 718 mg/day. Application of metformin resulted in a statistically significant reduction in total adipose tissue (4.8 ± 4.0 vs. 2.9 ± 4.4 kg, p = 0.03), waist circumference (96.4 ± 9.5 vs. 89.1 ± 11.1 cm, p = 0.003), and VAI (4.1 ± 2.4 vs. 2.5 ± 1.8, p = 0.006). Reduction in insulin requirement (0.7 ± 0.1 vs. 0.6 ± 0.2 units/kg/day, p = 0.02), fasting glycemia (166.5 ± 52.5 vs. 135.7 ± 48 mg/dl, p = 0.01), and postprandial glycemia (196.9 ± 74.3 vs. 137.1 ± 37.5 mg/dl, p = 0.00002) was also observed. In addition, decrease in triglyceride serum concentration (128.2 ± 52.9 vs. 94.0 ± 32.1 mg/dl, p = 0.002) and non-HDL cholesterol (154.5 ± 41.3 vs. 130.0 ± 39.7 mg/dl, p = 0.01) was achieved. Addition of metformin to insulin therapy of patients with type 1 diabetes mellitus and elevated adipose tissue content is safe and may lead to measurable clinical benefits.
Agnieszka Zawada; Dariusz Naskret; Pawel Burchardt; Pawel Niedzwiecki; Bogna Wierusz-Wysocka. The improvement of metabolic control after using metformin in patients with type 1 diabetes mellitus and excessive visceral fat tissue treated with intensive insulin therapy—pilot study. International Journal of Diabetes in Developing Countries 2015, 35, 400 -407.
AMA StyleAgnieszka Zawada, Dariusz Naskret, Pawel Burchardt, Pawel Niedzwiecki, Bogna Wierusz-Wysocka. The improvement of metabolic control after using metformin in patients with type 1 diabetes mellitus and excessive visceral fat tissue treated with intensive insulin therapy—pilot study. International Journal of Diabetes in Developing Countries. 2015; 35 (4):400-407.
Chicago/Turabian StyleAgnieszka Zawada; Dariusz Naskret; Pawel Burchardt; Pawel Niedzwiecki; Bogna Wierusz-Wysocka. 2015. "The improvement of metabolic control after using metformin in patients with type 1 diabetes mellitus and excessive visceral fat tissue treated with intensive insulin therapy—pilot study." International Journal of Diabetes in Developing Countries 35, no. 4: 400-407.
The cardiovascular diseases (CVD) are the leading cause of mortality in type 1 diabetes (DM1). Carotid intima-media thickness (IMT) has been approved as a marker of subclinical atherosclerosis. The aim of this prospective study was to evaluate the relationship between baseline diabetic knowledge after five-day teaching program and IMT in patients with (DM1) treated with intensive functional insulin therapy (IFIT) from the onset of the disease. The analysis included 79 subjects aged 23.4 ± 5.1 years with newly diagnosed DM1, participating in Poznan Prospective Study (PoProStu). The patients attended a five-day structured training program in IFIT at diagnosis, followed by a test consisting of 20 questions. After follow-up period of 11 years we evaluated the presence of microangiopathy and subclinical macroangiopathy. IMT of the right common carotid artery was determined using high resolution ultrasonography and calculated automatically with the Carotid Analyzer for Research program. After 11-year follow-up median intima-media thickness was 560 (IQR: 520-630) μm. We found a negative correlation between diabetes knowledge at baseline and IMT at the end of follow-up (r=-0.27, p=0.017). In multivariate linear regression model baseline diabetic knowledge test result was associated with IMT at follow-up, independently from sex, age, smoking status, presence of hypertension and diabetic kidney disease (all at follow-up) and from mean follow-up LDL-cholesterol concentrations and HbA1c results (β=-8, 95% CI -16, -1, p=0.037). Baseline diabetic knowledge after 5-day teaching program is an independent predictor of subclinical macroangiopathy in patients with DM1.
Aleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz; Stanislaw Pilacinski; Dariusz Naskret; Aleksandra Uruska; Bogna Wierusz-Wysocka. Baseline diabetic knowledge after 5-day teaching program is an independent predictor of subclinical macroangiopathy in patients with type 1 diabetes (Poznan Prospective Study). Advances in Medical Sciences 2014, 59, 240 -244.
AMA StyleAleksandra Araszkiewicz, Dorota Zozulinska-Ziolkiewicz, Stanislaw Pilacinski, Dariusz Naskret, Aleksandra Uruska, Bogna Wierusz-Wysocka. Baseline diabetic knowledge after 5-day teaching program is an independent predictor of subclinical macroangiopathy in patients with type 1 diabetes (Poznan Prospective Study). Advances in Medical Sciences. 2014; 59 (2):240-244.
Chicago/Turabian StyleAleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz; Stanislaw Pilacinski; Dariusz Naskret; Aleksandra Uruska; Bogna Wierusz-Wysocka. 2014. "Baseline diabetic knowledge after 5-day teaching program is an independent predictor of subclinical macroangiopathy in patients with type 1 diabetes (Poznan Prospective Study)." Advances in Medical Sciences 59, no. 2: 240-244.
There are scarce data about the effect of metformin on lipid profile in patients with type 1 diabetes.
Paweł Burchardt; Agnieszka Zawada; Piotr Tabaczewski; Dariusz Naskret; Jolanta Kaczmarek; Justyna Marcinkaniec; Bogna Wierusz‑Wysocka; Henryk Wysocki. Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. Polish Archives of Internal Medicine 2013, 123, 526 -532.
AMA StylePaweł Burchardt, Agnieszka Zawada, Piotr Tabaczewski, Dariusz Naskret, Jolanta Kaczmarek, Justyna Marcinkaniec, Bogna Wierusz‑Wysocka, Henryk Wysocki. Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. Polish Archives of Internal Medicine. 2013; 123 (10):526-532.
Chicago/Turabian StylePaweł Burchardt; Agnieszka Zawada; Piotr Tabaczewski; Dariusz Naskret; Jolanta Kaczmarek; Justyna Marcinkaniec; Bogna Wierusz‑Wysocka; Henryk Wysocki. 2013. "Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study." Polish Archives of Internal Medicine 123, no. 10: 526-532.
The aim of the study was to investigate whether changes in the level of oxidized LDL (oxLDL) over 2-years contribute to the development of subclinical macroangiopathy and/or microvascular complications in patients with DM1. Basic clinical and biochemical parameters and oxLDL level were measured in 70 patients at baseline and after 2 years of the study. In addition, an ultrasonographic study was performed to assess the carotid intima media thickness (IMT). Patients did not differ according to basic clinical and biochemical parameters at the beginning and after 2 years of the study. IMT increased (p=0.000001) whereas oxLDL level decreased (p=0.00001) in DM1 patients during 2 years. Multivariate regression analysis showed that oxLDL independently influences IMT in DM1 patients (β=0.454, R2=0.35). Further, positive correlations between oxLDL value and LDL-C concentration (r=0.585, p<0.05, n=70) and between oxLDL level and apo-B concentration have been established (r=0.610, p<0.05, n=70). Moreover, patients with chronic microvascular complications showed a higher value of IMT in comparison with patients without them (p=0.003). Our results provide the evidence that oxLDL accelerates atherosclerotic plaque formation and may contribute to the development of microvascular complications in DM1.
Malgorzata Wegner; Maria Piorunska-Stolzmann; Aleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz; Dariusz Naskret; Aleksandra Uruska; Bogna Wierusz-Wysocka. Does oxidized LDL contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes? Clinical Biochemistry 2012, 45, 1620 -1623.
AMA StyleMalgorzata Wegner, Maria Piorunska-Stolzmann, Aleksandra Araszkiewicz, Dorota Zozulinska-Ziolkiewicz, Dariusz Naskret, Aleksandra Uruska, Bogna Wierusz-Wysocka. Does oxidized LDL contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes? Clinical Biochemistry. 2012; 45 (18):1620-1623.
Chicago/Turabian StyleMalgorzata Wegner; Maria Piorunska-Stolzmann; Aleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz; Dariusz Naskret; Aleksandra Uruska; Bogna Wierusz-Wysocka. 2012. "Does oxidized LDL contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes?" Clinical Biochemistry 45, no. 18: 1620-1623.
The degeneration of retinal neurons and glial cells has recently been postulated in the pathogenesis of diabetic retinopathy. Optical coherence tomography (OCT) allows to perform qualitative and quantitative measurements of retinal thickness (RT) with identification of individual retinal layers.
Aleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz; Mikołaj Meller; Jadwiga Bernardczyk-Meller; Stanisław Piłaciński; Anita Rogowicz-Frontczak; Dariusz Naskręt; Bogna Wierusz-Wysocka. Neurodegeneration of the retina in type 1 diabetic patients. Polish Archives of Internal Medicine 2012, 122, 464 -470.
AMA StyleAleksandra Araszkiewicz, Dorota Zozulinska-Ziolkiewicz, Mikołaj Meller, Jadwiga Bernardczyk-Meller, Stanisław Piłaciński, Anita Rogowicz-Frontczak, Dariusz Naskręt, Bogna Wierusz-Wysocka. Neurodegeneration of the retina in type 1 diabetic patients. Polish Archives of Internal Medicine. 2012; 122 (10):464-470.
Chicago/Turabian StyleAleksandra Araszkiewicz; Dorota Zozulinska-Ziolkiewicz; Mikołaj Meller; Jadwiga Bernardczyk-Meller; Stanisław Piłaciński; Anita Rogowicz-Frontczak; Dariusz Naskręt; Bogna Wierusz-Wysocka. 2012. "Neurodegeneration of the retina in type 1 diabetic patients." Polish Archives of Internal Medicine 122, no. 10: 464-470.
Skin autofluorescence (AF) measured with an AF reader device is a noninvasive tool to measure the tissue accumulation of advanced glycation end products (AGEs). The aim of the study was to assess the association between AF and microvascular complications in type 1 diabetes mellitus (DM1).
Aleksandra Araszkiewicz; Dariusz Naskret; Pawel Niedzwiecki; Pawel Samborski; Bogna Wierusz-Wysocka; Dorota Zozulinska-Ziolkiewicz. Increased Accumulation of Skin Advanced Glycation End Products Is Associated with Microvascular Complications in Type 1 Diabetes. Diabetes Technology & Therapeutics 2011, 13, 837 -842.
AMA StyleAleksandra Araszkiewicz, Dariusz Naskret, Pawel Niedzwiecki, Pawel Samborski, Bogna Wierusz-Wysocka, Dorota Zozulinska-Ziolkiewicz. Increased Accumulation of Skin Advanced Glycation End Products Is Associated with Microvascular Complications in Type 1 Diabetes. Diabetes Technology & Therapeutics. 2011; 13 (8):837-842.
Chicago/Turabian StyleAleksandra Araszkiewicz; Dariusz Naskret; Pawel Niedzwiecki; Pawel Samborski; Bogna Wierusz-Wysocka; Dorota Zozulinska-Ziolkiewicz. 2011. "Increased Accumulation of Skin Advanced Glycation End Products Is Associated with Microvascular Complications in Type 1 Diabetes." Diabetes Technology & Therapeutics 13, no. 8: 837-842.
DOI: 10.20452/pamw.1025, Published online: March 01, 2011, Authors: Paweł Samborski, Dariusz Naskręt, Aleksandra Araszkiewicz, Paweł Niedźwiecki, Dorota Zozulińska‑Ziółkiewicz, Bogna Wierusz‑Wysocka
Paweł Samborski; Dariusz Naskret; Aleksandra Araszkiewicz; Paweł Niedźwiecki; Dorota Zozulinska-Ziolkiewicz; Bogna Wierusz‑Wysocka. Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes. Polish Archives of Internal Medicine 2011, 121, 67 -72.
AMA StylePaweł Samborski, Dariusz Naskret, Aleksandra Araszkiewicz, Paweł Niedźwiecki, Dorota Zozulinska-Ziolkiewicz, Bogna Wierusz‑Wysocka. Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes. Polish Archives of Internal Medicine. 2011; 121 (3):67-72.
Chicago/Turabian StylePaweł Samborski; Dariusz Naskret; Aleksandra Araszkiewicz; Paweł Niedźwiecki; Dorota Zozulinska-Ziolkiewicz; Bogna Wierusz‑Wysocka. 2011. "Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes." Polish Archives of Internal Medicine 121, no. 3: 67-72.
The aim of the study was to assess myocardial perfusion by means of non-invasive diagnostic methods and measurement of the plasma concentration of vascular endothelial growth factor (VEGF) in patients with long-lasting type 1 diabetes. The study was performed on 41 Type 1 diabetic patients (23 females, 18 males), aged 30 ± 7.6 with a duration of disease 15.2 ± 5.5 years. 17 patients exhibited microalbuminuria (10 females, 7 males) and 24 subjects were without microalbuminuria (13 females, 11 males). The methods used included a 24-h ECG tape, an exercise treadmill test, echocardiological evaluation with dobutamine and atropine challenge and single photon emission computer tomography (SPECT) at rest, and after dipyridamol induction of ischemia. All the exercise and stress echocardiography tests were negative. There were significant differences between microalbuminuric and normoalbuminuric subjects in the duration of their exercise tests (586.9 ± 110.5 vs. 664.9 ± 133.2 s, p = 0.027), performed work (11.4 ± 1.6.vs. 12.6 ± 1.8 METs, p = 0.045), achieved pulse limit (89.1 ± 3.6 vs. 92.6 ± 5.2%, p = 0.037), rest ejection fraction (55.8 ± 8.7 vs. 62.0 ± 4.4%, p = 0.040), abnormal changes in SPECT (53 vs. 21%, p = 0.047) and VEGF concentration (101.5 ± 7.8 vs. 75.15 ± 16.5 pg/ml, p < 0.05). The presence of retinopathy increased 12-fold the probability of significant changes in the SPECT (OR 12.1, 95% CI 1.38–105.64, p = 0.02) and nephropathy (OR 4.27; 95%CI 1.09–16.83, p = 0.03). Asymptomatic patients with long lasting type 1 diabetes may have disturbances in myocardial perfusion, especially these with microalbuminuria.
Dariusz Naskret; Dorota Zozulinska-Ziolkiewicz; Rafal Dankowski; Henryk Wysocki; Bogna Wierusz-Wysocka. Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients. Microvascular Research 2010, 80, 440 -444.
AMA StyleDariusz Naskret, Dorota Zozulinska-Ziolkiewicz, Rafal Dankowski, Henryk Wysocki, Bogna Wierusz-Wysocka. Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients. Microvascular Research. 2010; 80 (3):440-444.
Chicago/Turabian StyleDariusz Naskret; Dorota Zozulinska-Ziolkiewicz; Rafal Dankowski; Henryk Wysocki; Bogna Wierusz-Wysocka. 2010. "Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients." Microvascular Research 80, no. 3: 440-444.
Rafał Dankowski; Michał Wierzchowiecki; Dariusz Naskret; Marek Michalski; Magdalena Kandziora; Wojciech Biegalski; Kajetan Poprawski. Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus. Kardiologia Polska 2008, 66, 1 .
AMA StyleRafał Dankowski, Michał Wierzchowiecki, Dariusz Naskret, Marek Michalski, Magdalena Kandziora, Wojciech Biegalski, Kajetan Poprawski. Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus. Kardiologia Polska. 2008; 66 (3):1.
Chicago/Turabian StyleRafał Dankowski; Michał Wierzchowiecki; Dariusz Naskret; Marek Michalski; Magdalena Kandziora; Wojciech Biegalski; Kajetan Poprawski. 2008. "Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus." Kardiologia Polska 66, no. 3: 1.